Hodgkin Lymphoma
Conditions
Keywords
Brentuximab Vedotin, Immunotherapy, Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Reduced Intensity Conditioning, Allogeneic Stem Cell Transplantation
Brief summary
Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated). Following recovery, patients will receive a medication called Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that this treatment will be safe and well tolerated in children and young adults.
Interventions
DRUGBrentuximab Vedotin
Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below: * 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1 * 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1 * 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1 * 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
PROCEDUREAllogeneic Stem Cell Transplantation
Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
Sponsors
St. Baldrick's Foundation
New York Medical College
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* 45 years of age or less. * Patients with Hodgkin Lymphoma with either of the following: • Primary induction failure (failure to achieve initial CR) and/or primary refractory disease OR First, Second or Third relapse AND History of prior ablative auto HSCT or ineligible for an ablative auto HSCT or ≥25% residual disease after at least two reinduction chemotherapy cycles AND HLA matched family donor (6/6 or 5/6) or matched unrelated adult donor (MUD) (8/8) or matched umbilical cord blood unit (≥5/6) with prethaw cell dose of at least 3 x 107/kg TNC. * off other investigational therapy for one month prior to entry in this study. * adequate organ function
Exclusion criteria
* Patients with HD with 4th or greater CR, PR, and/or SD are ineligible. * Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo, radio, or immunotherapy are ineligible. * Patients who don't have an eligible donor are ineligible. * Women who are pregnant are ineligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 1 year | Patients will be followed for one year for adverse events related to the administration of study drug. |
| Overall Survival | 1 year | patients will be assessed for one year to determine survival status |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess feasibility of developing a bank of LMP-specific CTLs from healthy donors | 3 years | A bank of from identified EBV positive donors will be established for potential use in current and future clinical trials in LMP-positive lymphomas. Annual review will occur to assess the feasibility of recruiting healthy donors to help build this cell line bank. If there are no cell lines developed within the first year, an alternative design may be considered. |
Countries
United States
Outcome results
None listed